復宏漢霖/四環/康華/先健/國藥隨A股同業漲逾8%-10% 前者創上市新高 惟康希諾倒跌7%
內地醫藥生物/病毒防治、中藥、生物疫苗及流感板塊逆市升1.9%-4.1%。醫藥及醫療器械等相關板塊也普遍跑贏大市(恆指反覆續升0.4%)，尤其是主要開發及製銷心血管和外周血管疾病及紊亂所用先進微創介入醫療器械的先健科技(01302.HK)突破3月所創52周高位2.02元，最高見2.15元，創近兩年高現造2.07元，續漲10%，成交急增至6,420萬股，為幾年罕見，涉資近1.31億元。
在內地經營私營醫院的康華醫療(03689.HK)急彈14%報3.2元，股價重越10天及20天線。
國藥(01099.HK)也發力追落後，股價一舉升破20天、50天、10天及百天線(19.5-21.07元)，最高見21.8元，現造21元，急彈10.5%，成交急增至3,723萬股，為一年來最最多，涉資7.82億元。四環醫藥(00460.HK)突破百天線(0.84元)，最高見0.92元，現造0.91元，續漲9.6%，成交續增至8,299萬股，涉資7,369萬元。
由復星醫藥(02196.HK)分拆去年9月25日以每股49.6元上市的復宏漢霖-B(02696.HK)突破掛牌第三天盤中所創上市高位50.9元，最高見55.35元，現造54.7元，續升8.3%，成交額2,629萬元；其母企復星醫藥高見27.7元，現造27.6，回升5.1%。
上海醫藥(02607.HK)四連升，最高見13.7元，接近百天線(13.71元)，現造13.6元，續升逾2%。麗珠醫藥(01513.HK)四連升屢探頂，最高見37.35元，創兩年高，現造36.75元，續升2.8%。白雲山(00874.HK)曾一舉重越10天及百天線(20.95元及21.85元)，最高見22元，現造21.75元，續升3.6%。
康龍化成(03759.HK)、藍籌石藥(01093.HK)、石四藥(02005.HK)、康方生物-B(09926.HK)、康龍化成(03759.HK)、亞盛醫藥-B(06855.HK)、春立醫療(01858.HK)、華領醫藥-B(02552.HK)、歌禮製藥-B(01672.HK)、華潤醫藥(03320.HK)、東陽光藥(01558.HK)、藍籌中生製藥(01177.HK)及綠葉製藥(02186.HK)續彈逾2%-4%，後兩者最大，分別高見14.68元及高見4.76元，前者為最強藍籌，後者回補3月9日部分下跌裂口(4.82-4.74元)。
不過，維亞生物(01873.HK)、福森藥業(01652.HK)、君實生物醫藥-B(01877.HK)、復旦張江生物醫藥(01349.HK)、希瑪眼科(03309.HK)、康寧傑瑞製藥-B(09966.HK)、中國抗體製藥-B(03681.HK)及康希諾生物-B(06185.HK)依次跌1.5%-7%，後者最傷，該股承過去兩天升勢今早高開升至204.8元乏力，掉頭失守20天線(186.4元)，最低見183.1元，現造185.7元，倒跌7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
